Trials / Not Yet Recruiting
Not Yet RecruitingNCT07511023
Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal cancer.
Detailed description
Primary Objectives To evaluate the overall response rate for Sacituzumab tirumotecan in participants with treatment refractory unresectable and/or metastatic anal cancer. Secondary Objectives * To estimate progression-free survival for Sacituzumab tirumotecan in participants with treatment refractory unresectable and/or metastatic anal cancer. * To describe the disease control rate using criteria for Sacituzumab tirumotecan in participants with treatment-refractory unresectable and/or metastatic anal cancer. * To summarize safety and tolerability using CTCAE version 5.0 for Sacituzumab tirumotecan in participants with treatment-refractory unresectable and/or metastatic anal cancer.
Conditions
- Phase 2
- Sacituzumab Tirumotecan
- Refractory Metastatic
- Unresectable Squamous
- Cell Carcinoma of the Anus/ Rectum
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacituzumab Tirumotecan | Given by IV |
Timeline
- Start date
- 2026-09-25
- Primary completion
- 2031-03-01
- Completion
- 2033-03-01
- First posted
- 2026-04-06
- Last updated
- 2026-04-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07511023. Inclusion in this directory is not an endorsement.